Shares of Geron Co. (NASDAQ:GERN) were up 5.3% during mid-day trading on Wednesday . The company traded as high as $1.81 and last traded at $1.79. Approximately 2,449,611 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 3,020,871 shares. The stock had previously closed at $1.70.

A number of analysts have issued reports on GERN shares. B. Riley raised Geron from a “neutral” rating to a “buy” rating and raised their target price for the stock from $1.50 to $3.25 in a research note on Thursday, January 31st. BTIG Research started coverage on Geron in a research note on Tuesday, February 12th. They issued a “buy” rating and a $4.00 target price for the company. BidaskClub raised Geron from a “hold” rating to a “buy” rating in a research note on Saturday, March 16th. Finally, Needham & Company LLC raised Geron from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $3.01.

The company has a market capitalization of $309.62 million, a PE ratio of -11.19 and a beta of 2.93.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.23 million. Geron had a negative return on equity of 17.53% and a negative net margin of 3,713.04%. On average, equities analysts anticipate that Geron Co. will post -0.34 EPS for the current fiscal year.

In related news, EVP Melissa Kelly Behrs sold 120,635 shares of the firm’s stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $2.00, for a total transaction of $241,270.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.20% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the stock. Parametric Portfolio Associates LLC increased its position in shares of Geron by 13.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 53,874 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 6,335 shares during the last quarter. Swiss National Bank increased its position in shares of Geron by 4.6% during the 1st quarter. Swiss National Bank now owns 339,600 shares of the biopharmaceutical company’s stock worth $564,000 after purchasing an additional 14,900 shares during the last quarter. Amalgamated Bank acquired a new stake in shares of Geron during the 4th quarter worth about $25,000. SVA Plumb Wealth Management LLC increased its position in shares of Geron by 98.8% during the 4th quarter. SVA Plumb Wealth Management LLC now owns 50,300 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 25,000 shares during the last quarter. Finally, HRT Financial LLC increased its position in shares of Geron by 192.6% during the 4th quarter. HRT Financial LLC now owns 40,098 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 26,393 shares during the last quarter. 31.99% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Geron (GERN) Trading Up 5.3%” was first reported by Marea Informative and is the property of of Marea Informative. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.mareainformativa.com/news/2019/05/15/geron-gern-trading-up-5-3.html.

About Geron (NASDAQ:GERN)

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Further Reading: Mutual Funds

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.